Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 1/20 | 0.49 |
| ▸ | GABRD | O14764 | 1/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.49 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.49 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.49 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.49 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.49 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.49 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.49 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.49 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.49 |
| ▸ | GABRE | P78334 | 1/20 | 0.49 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.49 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.49 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.49 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.49 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | GSK3A | P49840 | 2/20 | 0.43 |
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6869104 | 0.88 | GABRP (0.49) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL6868738 | 0.87 | IDO1 (0.47) | GSK3BALDH1A1MEN1KMT2ACSF1R | |
| SCHEMBL6952882 | 0.86 | CTSV (0.52) | PKMGSK3BALDH1A1MEN1KMT2A | |
| SCHEMBL4425448 | 0.73 | GSK3B (0.51) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL11625660 | 0.73 | HCRTR1 (0.50) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL9269177 | 0.69 | MAP2 (0.62) | HCRTR1PKMGSK3AGSK3BALDH1A1 | |
| SCHEMBL15797025 | 0.68 | IMPDH2 (0.49) | ALDH1A1MEN1KMT2AMAPK1CLK4 | |
| SCHEMBL17396637 | 0.67 | GABRA1 (0.59) | GABRA1GABRG2GABRB3GABRA5GABRA2 | |
| SCHEMBL7230887 | 0.67 | LMNA (0.50) | GSK3AGSK3BALDH1A1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL7736818 | 0.67 | ADRA2A (0.46) | ALDH1A1MEN1KMT2ACSF1RPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1465610-A1 | USE OF A GSK-3BETA INHIBITOR IN THE MANUFACTURE OF A MEDICAMENT FOR INCREASING BONE FORMATION | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-13 | — | — | EP | disclosed |
| WO-2003057202-A1 | USE OF A GSK-3BETA INHIBITOR IN THE MANUFACTURE OF A MEDICAMENT FOR INCREASING BONE FORMATION | F. HOFFMANN-LA ROCHE AG (CH) | 2003-07-17 | — | — | WO | disclosed |
| EP-1307447-A2 | 3-INDOLYL-4-PHENYL-1H-PYRROLE-2,5-DIONE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-07 | — | — | EP | disclosed |
| US-20020188018-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | GONG LEYI (US) | 2002-12-12 | — | — | US | disclosed |
| WO-2002010158-A2 | 3-INDOLYL-4-PHENYL-1H-PYRROLE-2,5-DIONE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020188018-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | GSK3B, GSK3A, PYGL | GABRP 1796/4885GABRD 3093/4885GABRA1 3330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.